Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction.
Lachaux M, Barrera-Chimal J, Nicol L, Rémy-Jouet I, Renet S, Dumesnil A, Wecker D, Richard V, Kolkhof P, Jaisser F, Ouvrard-Pascaud A, Mulder P. Lachaux M, et al. Among authors: kolkhof p. Diabetes Obes Metab. 2018 Oct;20(10):2399-2407. doi: 10.1111/dom.13393. Epub 2018 Jun 27. Diabetes Obes Metab. 2018. PMID: 29862614
Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.
Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A, Brinker M, Kolkhof P, Schloemer P, Lay-Flurrie J, Viswanathan P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD. Vaduganathan M, et al. Among authors: kolkhof p. Nat Med. 2024 Oct 28. doi: 10.1038/s41591-024-03372-1. Online ahead of print. Nat Med. 2024. PMID: 39468366 No abstract available.
Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.
Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Pérez S, Heckroth H, Nitsche A, Ergüden JK, Gielen-Haertwig H, Schlemmer KH, Mittendorf J, Paulsen H, Platzek J, Kolkhof P. Bärfacker L, et al. Among authors: kolkhof p. ChemMedChem. 2012 Aug;7(8):1385-403. doi: 10.1002/cmdc.201200081. Epub 2012 Jul 12. ChemMedChem. 2012. PMID: 22791416
A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.
Katayama S, Yamada D, Nakayama M, Yamada T, Myoishi M, Kato M, Nowack C, Kolkhof P, Yamasaki Y; ARTS-DN Japan study group. Katayama S, et al. Among authors: kolkhof p. J Diabetes Complications. 2017 Apr;31(4):758-765. doi: 10.1016/j.jdiacomp.2016.11.021. Epub 2016 Dec 14. J Diabetes Complications. 2017. PMID: 28025025 Free article. Clinical Trial.
Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1.
Barrera-Chimal J, André-Grégoire G, Nguyen Dinh Cat A, Lechner SM, Cau J, Prince S, Kolkhof P, Loirand G, Sauzeau V, Hauet T, Jaisser F. Barrera-Chimal J, et al. Among authors: kolkhof p. J Am Soc Nephrol. 2017 Apr;28(4):1216-1226. doi: 10.1681/ASN.2016040477. Epub 2017 Jan 13. J Am Soc Nephrol. 2017. PMID: 28087726 Free PMC article.
109 results